{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:54:14Z","timestamp":1791435254891,"version":"4.3.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Health, National Eye Institute, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41433-018-0283-0","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T13:38:59Z","timestamp":1543412339000},"page":"629-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis"],"prefix":"10.1038","volume":"33","author":[{"given":"Courtney","family":"McCracken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Travers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneka","family":"Stryker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tommasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Rouster-Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampath","family":"Prahalad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Drews-Botsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-6464","authenticated-orcid":false,"given":"Sheila T.","family":"Angeles-Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"283_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","volume":"143","author":"JE Thorne","year":"2007","unstructured":"Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143:840\u20136.","journal-title":"Am J Ophthalmol"},{"key":"283_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajo.2006.11.025","volume":"143","author":"F Woreta","year":"2007","unstructured":"Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647\u201355.","journal-title":"Am J Ophthalmol"},{"key":"283_CR3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","volume":"21287","author":"JE Thorne","year":"2016","unstructured":"Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, et al. Prevalence of noninfectious uveitis in the United States. JAMA Ophthalmol. 2016;21287:1237\u201345.","journal-title":"JAMA Ophthalmol"},{"key":"283_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-015-0018-8","volume":"13","author":"ST Angeles-Han","year":"2015","unstructured":"Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Rouster-Stevens K, et al. Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA-associated uveitis. Pediatr Rheumatol Online J. 2015;13:1\u201310.","journal-title":"Pediatr Rheumatol Online J"},{"key":"283_CR5","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3899\/jrheum.130302","volume":"40","author":"ST Angeles-Han","year":"2013","unstructured":"Angeles-Han ST, Pelajo CF, Vogler LB, Rouster-Stevens K, Kennedy C, Ponder L, et al. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. J Rheumatol. 2013;40:2088\u201396.","journal-title":"J Rheumatol"},{"key":"283_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","volume":"120","author":"2ndAC Gregory","year":"2013","unstructured":"Gregory 2ndAC, Kempen JH, Daniel E, Kacmaz RO, Foster CS, Jabs DA, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186\u201392.","journal-title":"Ophthalmology"},{"key":"283_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/bjo.86.1.51","volume":"86","author":"C Edelsten","year":"2002","unstructured":"Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:51\u20136.","journal-title":"Br J Ophthalmol"},{"key":"283_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ajo.2008.11.009","volume":"147","author":"GN Holland","year":"2009","unstructured":"Holland GN, Denove CS, Yu F. Chronic anterior uveitis in children: clinical characteristics and complications. Am J Ophthalmol. 2009;147:667\u201378 e5.","journal-title":"Am J Ophthalmol"},{"key":"283_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","volume":"35","author":"R Bou","year":"2015","unstructured":"Bou R, Adan A, Borras F, Bravo B, Calvo I, De Inocencio J, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35:777\u201385.","journal-title":"Rheumatol Int"},{"key":"283_CR10","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","volume":"32","author":"A Heiligenhaus","year":"2012","unstructured":"Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121\u201333.","journal-title":"Rheumatol Int"},{"key":"283_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785\u201396 e3.","journal-title":"Ophthalmology"},{"key":"283_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12969-016-0069-5","volume":"14","author":"LA Henderson","year":"2016","unstructured":"Henderson LA, Zurakowski D, Angeles-Han ST, Lasky A, Rabinovich CE, Lo MS. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016;14:9.","journal-title":"Pediatr Rheumatol Online J"},{"key":"283_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0022-3476(98)70232-X","volume":"133","author":"AH Weiss","year":"1998","unstructured":"Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998;133:266\u20138.","journal-title":"J Pediatr"},{"key":"283_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/112067210701700509","volume":"17","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17:743\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"283_CR15","first-page":"362","volume":"32","author":"I Foeldvari","year":"2005","unstructured":"Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362\u20135.","journal-title":"J Rheumatol"},{"key":"283_CR16","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637\u201346.","journal-title":"N Engl J Med"},{"key":"283_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","volume":"52","author":"G Simonini","year":"2013","unstructured":"Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatol. 2013;52:825\u201331.","journal-title":"Rheumatol"},{"key":"283_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/acr.22214","volume":"66","author":"G Simonini","year":"2014","unstructured":"Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res. 2014;66:1073\u201384.","journal-title":"Arthritis Care Res"},{"key":"283_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3899\/jrheum.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74\u20139.","journal-title":"J Rheumatol"},{"key":"283_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","volume":"113","author":"RT Rajaraman","year":"2006","unstructured":"Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308\u201314.","journal-title":"Ophthalmology"},{"key":"283_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","volume":"113","author":"P Kahn","year":"2006","unstructured":"Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860\u20134 e2.","journal-title":"Ophthalmology"},{"key":"283_CR22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ajo.2007.08.018","volume":"144","author":"SP Ardoin","year":"2007","unstructured":"Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144:844\u20139.","journal-title":"Am J Ophthalmol"},{"key":"283_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","volume":"149","author":"LB Vazquez-Cobian","year":"2006","unstructured":"Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572\u20135.","journal-title":"J Pediatr"},{"key":"283_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/560632","volume":"2013","author":"Carmen Garc\u00eda-De-Vicu\u00f1a","year":"2013","unstructured":"Garc\u00eda-De-Vicu\u00f1a C, D\u00edaz-Llopis M, Salom D, Bou R, D\u00edaz-Cascajosa J, Cordero-Coma M, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.","journal-title":"Mediators of Inflammation"},{"key":"283_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaapos.2013.06.009","volume":"17","author":"L Bravo-Ljubetic","year":"2013","unstructured":"Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gomez J, Merino R. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17:456\u20139.","journal-title":"J AAPOS"},{"key":"283_CR26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00417-013-2275-x","volume":"251","author":"A Magli","year":"2013","unstructured":"Magli A, Forte R, Navarro P, Russo G, Orlando F, Latanza L, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"283_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","volume":"47","author":"P Tynjala","year":"2008","unstructured":"Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatol. 2008;47:339\u201344.","journal-title":"Rheumatol"},{"key":"283_CR28","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"283_CR29","doi-asserted-by":"crossref","unstructured":"Jabs DA Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509\u201316.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"283_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/09273948.2013.815785","volume":"21","author":"AT Vitale","year":"2013","unstructured":"Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm. 2013;21:478\u201385.","journal-title":"Ocul Immunol Inflamm"},{"key":"283_CR31","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O\u2019Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012\u201321.","journal-title":"Arthritis Rheum"},{"key":"283_CR32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynj\u00e4l\u00e4","year":"2011","unstructured":"Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Tarkiainen M, Kr\u00f6ger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605\u201312.","journal-title":"Ann Rheum Dis"},{"key":"283_CR33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0161-6420(97)30329-7","volume":"104","author":"MR Dana","year":"1997","unstructured":"Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104:236\u201344.","journal-title":"Ophthalmology"},{"key":"283_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/rheumatology\/kem053","volume":"46","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: Suggested modification of the current screening guidelines. Rheumatology. 2007;46:1015\u20139.","journal-title":"Rheumatology"},{"key":"283_CR35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ajo.2010.01.014","volume":"149","author":"VK Ayuso","year":"2010","unstructured":"Ayuso VK, Ten Cate HA, van der Does P, Rothova A, de Boer JH. Male gender and poor visual outcome in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2010;149:987\u201393.","journal-title":"Am J Ophthalmol"},{"key":"283_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1755-3768.2009.01815.x","volume":"90","author":"ME Zannin","year":"2012","unstructured":"Zannin ME, Buscain I, Vittadello F, Martini G, Alessio M, Orsoni JG, et al. Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol. 2012;90:91\u20135.","journal-title":"Acta Ophthalmol"},{"key":"283_CR37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ajo.2015.08.002","volume":"160","author":"ST Angeles-Han","year":"2015","unstructured":"Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Travers C, et al. The association of race with childhood uveitis. Am J Ophthalmol. 2015;160:919\u2013928.e1.","journal-title":"Am J Ophthalmol"},{"key":"283_CR38","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3899\/jrheum.161336","volume":"44","author":"G Simonini","year":"2017","unstructured":"Simonini G, Bracaglia C, Cattalini M, Taddio A, Brambilla A, De Libero C, et al. Predictors of relapse after discontinuing systemic treatment in childhood autoimmune chronic uveitis. J Rheumatol. 2017;44:822\u20136.","journal-title":"J Rheumatol"},{"key":"283_CR39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ajo.2010.01.016","volume":"149","author":"V Kalinina Ayuso","year":"2010","unstructured":"Kalinina Ayuso V, ten Cate HAT, van der Does P, Rothova A, de Boer JH. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2010;149:994\u2013.e5.","journal-title":"Am J Ophthalmol"},{"key":"283_CR40","first-page":"2446","volume":"29","author":"F Zulian","year":"2002","unstructured":"Zulian F, Martini G, Falcini F, Gerloni V, Zannin ME, Pinello L, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol. 2002;29:2446\u201353.","journal-title":"J Rheumatol"},{"key":"283_CR41","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932\u201343.","journal-title":"N Engl J Med"},{"key":"283_CR42","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183\u201392.","journal-title":"Lancet"},{"key":"283_CR43","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1542\/peds.2006-0421","volume":"117","author":"J Cassidy","year":"2006","unstructured":"Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117:1843\u20135.","journal-title":"Pediatrics"},{"key":"283_CR44","first-page":"356","volume":"14","author":"J Cobb","year":"2014","unstructured":"Cobb J, Cule E, Moncrieffe H, Hinks A, Ursu S, Patrick F, et al. Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharm J. 2014;14:356\u201364.","journal-title":"Pharm J"},{"key":"283_CR45","first-page":"257120","volume":"2010","author":"ML Becker","year":"2010","unstructured":"Becker ML, Leeder JS. Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate. Hum Genomics Proteom. 2010;2010:257120.","journal-title":"Hum Genomics Proteom"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0283-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:53Z","timestamp":1684616753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-018-0283-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1038\/s41433-018-0283-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"5 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Steven Yeh is a consultant for Santen, Inc. and Clearside Biomedical. Dr. Sampath Prahalad is on an advisory committee for Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}